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Summary
Objective: To compare the effect of celecoxib vs placebo treatment on clinical and gait variables in knee osteoarthritis (OA) patients; focusing
on the efﬁciency of the locomotor mechanism.
Methods:
Study design: A prospective, randomised, double-blind placebo-controlled trial.
Patients: Eight adult patients with painful OA of the knee.
Outcome measures: Clinical assessment included knee pain assessed by the visual analogue scale, range of knee motion assessed by
goniometer, and locomotor function status assessed by a Knee Score Scale. Gait was assessed by means of instrumented analysis including
synchronous kinematic, dynamic, electromyographic, and energetic recordings.
Statistical analysis: The effect of treatment on the primary variable, the efﬁciency of the locomotor mechanism, and on secondary clinical and
gait variables was assessed by the Hills and Armitage non-parametric approach.
Results: Celecoxib treatment improved the efﬁciency of the locomotor mechanism signiﬁcantly. Among the secondary outcome measures
assessed, celecoxib treatment improved walking cadence and reduced the knee pain signiﬁcantly.
Conclusion: This study shows that celecoxib is effective in improving locomotor function and pain in patients with knee OA.
ª 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIntroduction
Osteoarthritis (OA) is the most common joint disorder,
accounting for signiﬁcant disability and health care expen-
diture. Nonsteroidal anti-inﬂammatory drugs (NSAID) have
long been used to treat pain and joint inﬂammation and to
improve gait1. Celecoxib and rofecoxib were subsequently
introduced as highly selective inhibitors of cyclooxygenase-
2 (COX-2) which improved pain and inﬂammation with less
gastrointestinal side effects2. The efﬁcacy of celecoxib and
rofecoxib on pain, stiffness, and joint inﬂammation has been
established1,3. The gait of patients with knee OA is affected
by pain and stiffness, but quantiﬁable outcome measures
are necessary if one is to compare the beneﬁts of different
treatments4. Only limited data are currently available on the
effects of NSAIDs on gait variables4,5 and there is none on
COX-2 inhibitors in patients with knee OA. We hypo-
thesised that knee stiffness and pain can affect
the kinematics of the lower limbs. It is possible to study
the effects of these abnormalities on the efﬁciency of the
locomotor mechanism using measurement of mechanical
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measurements may be relevant to disability in ambulatory
patients and may also be useful in clinical research to
improve knowledge of the effects of treatment. By studying
the energy changes of the centre of body mass (CMb) it is
also possible to gain further insight into the mechanisms
responsible for abnormal gaits and whether or not the
normal walking mechanism is preserved in OA patients.
The aim of our study was to compare the effect of celecoxib
vs placebo treatment on clinical, kinematic, electromyograph-
ic (EMG),mechanical and energetic gait variables in kneeOA
patients in a randomised, double blind, cross-over vs placebo
trial, focusing speciﬁcally on the effects of treatment on the
efﬁciency of the locomotor mechanism.
Patients and methods
PATIENTS
Eight adult patients (ﬁve women and three men, mean
age of 65.5G 9 years, mean weight of 74.9G 14 kg, mean
height of 1.65G 0.1 m; Table I) with painful and disabling
OA of the knee were recruited consecutively from a rheu-
matology department by a single rheumatologist. All
patients had radiological evidence of OA in the knee (grade
II to IV on the Kellgren-Lawrence scale). All patients
had difﬁculty in walking on ﬂat ground but were able
to walk without aids. Exclusion criteria were similar to
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medical/arthritic diseases which could interfere with the
assessments, such as secondary inﬂammatory arthritis,
gout, isolated patellofemoral disease, a history of acute
ligamentous or meniscal injury within the previous 2 years,
or athroscopy in the 3 months prior to study entry. Oral or
intramuscular injection of corticosteroids within 4 weeks
before study entry was also an exclusion criterion. Patients
with hypersensitivity to one of the ingredients of celecoxib
or rescue medication, patients with cardiological, respiratory
or neurological disease, with gross obesity (Body Mass
IndexO 40), or with mental deﬁcit were not included in the
study. Patients with severe renal or hepatic insufﬁciency
were also excluded, as were patients with acute or
suspected gastrointestinal bleeding, or active gastric or
duodenal ulcer.
STUDY DESIGN
This prospective, randomised, double blind, placebo-
controlled study was conducted over an 8-month period in
accordance with the principle of Good Clinical Practice
guidelines of the regional drug control administration
(Pﬁzer, Belgium). All patients gave informed consent and
were recruited on a volunteer basis. The local ethics
committee approved this study.
Seven days before the ﬁrst clinical assessment (day 0,
visit 1), the patients stopped their previous NSAID therapy
to allow a full washout period based on the half-life of the
molecule3. On visit 2 (day 7) and visit 3 (day 21), clinical
and gait assessments were performed, i.e., at the start of,
and 14 days after, celecoxib 200 mg or placebo treatment.
The patients then stopped treatment for a further 7 days to
allow another washout period. They then started the second
Table I
Anthropomorphic characteristics of patients
Number Sex
(F/M)
Height
(m)
Weight
(kg)
BMI
(kgm2)
Age
(years)
1 F 1.62 61 23.2 62
2 F 1.54 63 26.6 55
3 M 1.79 89 27.8 66
4 F 1.67 59.5 21.3 54
5 F 1.60 68 26.6 79
6 F 1.51 82 36.0 62
7 M 1.75 79 25.8 71
8 M 1.72 84.5 28.6 75
MeanGSD 1.65G 0.1 74.9G 14 27.0G 4 65.5G 9
F: female, M: male, BMI: Body Mass IndexZweight/height2.phase of the study taking the treatment they had not received
during the ﬁrst phase, i.e., placebo or celecoxib, for 14 days.
On visit 4 (day 42), the fourth clinical examination and the
third gait assessment were performed. Each assessment
wasmade in the same conditions by the same examiner. The
experimental design is summarised in Table II.
TRIAL PROTOCOL
In our trial protocol, we have deﬁned the efﬁciency of the
locomotor mechanism as the primary outcome measure.
The other clinical and gait variables were deﬁned as
secondary outcome measures. We have tested the effect
of celecoxib on primary and secondary outcome measures
separately.
TREATMENT
Patients were randomly assigned to one of two groups
(COX-2 or placebo). A single dose of celecoxib 200 mg or
placebo provided by Pﬁzer, Belgium, was ingested with the
evening meal once a day for 14 days. Paracetamol
(6! 500 mg/day max) was the only pain relief allowed if
needed, and if taken was stopped 12 h before each
assessment.
OUTCOME MEASURES
Clinical assessment
A safety evaluation was undertaken for each patient at
each visit (1 to 4), noting the incidence and type of side
effects. Clinical assessment included an estimate of knee
pain on a 100 mm visual analogue scale (VAS). The range
of knee motion was measured by a manual goniometer and
locomotor function status assessed by the Knee Score
Scale7.
Gait assessment
Gait was assessed at visits 2, 3, and 4 by 3D
instrumented analysis including synchronous kinematic,
dynamic, EMG, and energetic recordings. Patients were
instructed to walk at their self-selected speed. Foot-switch
sensors were attached under the sole of the patients’ feet
and recorded at 1000 Hz (Elite V5, Italy). These data were
necessary to compute the global temporal parameters, i.e.,
walking speed, stride length, and cadence. Segmental
kinematics were measured with the Elite system (Elite V5,
Italy) and recorded at 50 Hz. Four CCD infrared cameras
measured the coordinates, in the three spatial planes, of 19Table II
Schematic representation of outcome measurements in an AB/BA cross-over trial
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marks to compute angular displacements of joint seg-
ments8. Each patient recorded 10G 2 trials. All trials were
normalised to 100%; 0% corresponding to the initial foot
contact of the OA leg. On the OA lower limb, several
angular parameters of the knee (K1-ﬂexion at heel strike;
K2-maximum ﬂexion at loading response; K3-maximum
ﬂexion in swing phase) were assessed9.
The ground reaction forces (GRF) were simultaneously
recorded by a 1.8 m long, 0.6 m wide strain-gauge force
platform (Pharos System, USA) at 50 Hz mounted at
ground level in the middle of the walkway (10 m). The
external mechanical work, Wext, i.e., the work performed by
the muscles to lift and accelerate the CMb relative to the
surroundings during walking, was computed from the GRF
following the method described in detail by Cavagna10,
validated by Willems et al.11, and adapted to pathological
gait12. The 3D accelerations of the CMb were computed
from the vertical, lateral, and forward raw components of the
GRF and the mass of the patient. The mathematical
integration of the 3D accelerations gave the 3D speeds of
the CMb, allowing computation of the CMb kinetic energy
due to forward (Ekf), vertical (Ekv), and lateral (Ekl) speeds.
A second mathematical integration of vertical CMb speed
gave the vertical displacement (Sv) of the CMb. From the
vertical displacement (Sv) of the CMb, the instantaneous
gravitational potential energy (Ep) was computed. The total
external mechanical energy of the CMb was computed as
the sum of gravitational potential energy and kinetic ener-
gies. The increments of Ekf, Ekv, Ekl, Ep represented the
positive work necessary to accelerate the CMb in the three
directions and to lift the CMb (Wekf, Wekv, Wekl, Wep), and
calculated during a stride. Wext during gait was determined
by summing the increments of the total mechanical energy
curve during a stride. Wekf, Wekv, Wekl, Wep, and Wext are
expressed per unit distance and per kg body mass. The
Recovery, quantifying the amount of energy-saving transfer
between gravitational potential energy and kinetic energy of
the CMb, i.e., an index reﬂecting the efﬁciency of the
pendulum-like mechanism of walking, was calculated as10:
RecoveryZ100)
jWekfjCjWekvjCjWekljC
WepWext
jWekfjCjWekvjCjWekljC
Wep
where jWekfjCjWekvjCjWekljC
Wep, represents the maxi-
mum work one should do without energy shift, and the work
actually done, Wext. A 100% recovery would require the
kinetic and potential curves to be exactly opposite in phase
and of equal shape and amplitude according to a purely
ballistic movement. In this case, the frequency of ballistic
movement ( f0) is calculated as:
f0Z2p)
ﬃﬃﬃ
l
g
s
where l is the leg length of the subject, i.e., the distance
between the greater trochanter and the ground and g the
gravitational acceleration.
The electrical activity of the Rectus Femoris (RF) and
Biceps Femoris (BF) muscles was recorded by a telemetric
EMG system (BTS, Italy) with surface electrodes. The
signal was digitised at 1000 Hz, full-wave rectiﬁed and
ﬁltered (bandwidth 25e300 Hz). The onset and cessation of
muscle activity were visually determined. The EMG activity
of each muscle was normalised in 100% of stride time. The
co-contraction time index between RF and BF muscles
was temporally quantiﬁed as the percentage of the strideduring which antagonistic muscles were simultaneously
activated.
Force, kinematics, EMG and foot-switch signals were
recorded simultaneously and synchronised by two photo-
cells. The information from photocells, placed at the level of
the neck of the patient to avoid interference with move-
ments of the upper limbs, was used to calculate the mean
forward speed by dividing the distance between the
photocells, i.e., 1.8 m or the length of platform, by the time
taken to cross them.
Directly after the level ground evaluation, the assessment
of metabolic energy cost was performed on a motor driven
treadmill (Mercury LT med, Germany). Breath by breath
rates of oxygen consumption and carbon dioxide production
were measured with an ergospirometer (Quark b2, Italy).
Values were automatically converted by a software program
(Cosmed Quark B2 win, v 5.1.a) to standard temperature,
pressure, and dry oxygen consumption. The measurement
of the rate of oxygen consumption involved a rest period
with the patient standing on the treadmill, followed by
a walking period at a gait speed equivalent to the average
gait speed adopted during assessment on level ground.
The patients were asked to walk for at least 2 min after they
reached steady state. The respiratory quotient (RQ),
determined by the ratio between the rate of carbon dioxide
production and the rate of oxygen consumption, was always
less than one. Joules of energy expended per litre of
oxygen consumed were computed, depending on the RQ.
The net energy rate was the energy expended during gait
minus the energy expended at rest expressed in
J kg1 min1. The net rate of energy expenditure was then
divided by the gait speed of the patient to obtain the net
energy cost of gait (C ) expressed in J kg1 m1.
STATISTICAL ANALYSIS
Our data were computed by an independent, blinded
statistician (Data Investigation Company Europe, Belgium).
The effects of treatment (celecoxib vs placebo treatment)
on the primary variable, i.e., the effect on the efﬁciency of
the locomotor mechanism was assessed using the Hills and
Armitage non-parametric approach13 as speciﬁed in the trial
protocol. Secondary outcomes including the effects of
treatment on clinical and gait variables were also assessed
by the Hills and Armitage non-parametric approach. The
Hills and Armitage non-parametric approach involves initial
calculation, for each patient, at what has been referred to as
a basic estimator. This is the difference between the two
treatments (A or COX-2 vs B or placebo treatment) or
treatment effect for a given patient. This procedure ignores
the baseline but can be considered safe as there is no
problem of carry-over13.
Results
The statistical analysis of results is presented in Table III.
The results showed that a treatment effect was present. The
primary variable deﬁned in our initial protocol was signiﬁ-
cantly improved by celecoxib treatment. In fact the
efﬁciency of the locomotor mechanism expressed by the
recovery index [see Fig. 1(C)] was signiﬁcantly improved
(PZ 0.03) by celecoxib treatment (44G 5% at placebo and
53G 4% at celecoxib visits). The recovery index increased
because of a signiﬁcantly better phase time course
(PZ 0.03) between potential and kinetic energy changes.
At placebo visit, the CMb potential energy reached its
209Osteoarthritis and Cartilage Vol. 13, No. 3maximum value 8.1G 6 ms before the CMb kinetic energy
reached its minimum. After celecoxib treatment, the CMb
potential energy reached its maximum value 1.7G 1 ms
before the CMb kinetic energy reached its minimum. This
time course reﬂects an improved locomotor mechanism.
Two secondary outcome measures were also improved
by celecoxib treatment. The mean VAS score of knee pain
[see also Fig. 1(A)] was signiﬁcantly (PZ 0.03) decreased
between placebo (34G 31) and celecoxib (22.5G 15)
visits. The mean cadence [see Fig. 1(B)] was signiﬁcantly
(PZ 0.03) increased between placebo (88G 5 step min1)
and celecoxib (95G 5 step min1) visits. However, the other
secondary outcome variables were not improved by the
treatment. The mean range of knee motion (121G 14( in
COX-2 group vs 122G 14( in placebo group) and
the median knee function score (90 [range 45e100] in
COX-2 group vs 95 [range 45e100] in placebo group)
were not affected by treatment. The mean spontaneous
walking speed (2.6G 0.6 km h1 in COX-2 group vs
2.5G 0.4 km h1 in placebo group) and the step length
(0.48G 0.1 m in COX-2 group vs 048G 0.07 m in placebo
group) were unchanged. The mean knee angular displace-
ment at initial contact (K1: 6G 6( in COX-2 group vs 6G 9(
in placebo group), at maximum ﬂexion at loading response
(K2: 12G 7( in COX-2 group vs 10G 10( in placebo
group), and at maximum ﬂexion in swing phase (K3: 49G 6(
in COX-2 group vs 48G 13( in placebo group) were not
affected by treatment. The mechanical work (Wext: 0.35G
0.07 J kg1 m1 in COX-2 group vs 0.43G 0.1 J kg1 m1 in
placebo group) and the cost (C: 3.35G 2 J kg1 m1 in
COX-2 group vs 3.71G 2.7 J kg1 m1 in placebo group)
were not signiﬁcantly improved after celecoxib treatment.
The time of co-contraction was not affected by treatment
(40G 10% in COX-2 group vs 36G 8% in placebo group).
Discussion
The clinical efﬁcacy of celecoxib in reducing knee pain in
patients with OA has been demonstrated in previous
studies1,6. However the efﬁcacy of celecoxib on measurable
Table III
Statistical analysis of results of Hills and Armitage non-parametric
approach on primary and secondary clinical and gait variables
Treatment effect
(P value)
Primary variable
Efﬁciency of the locomotor
mechanism (Recovery)
0.030
Secondary variables
Clinical assessment
VAS knee pain 0.030
Range of knee motion 0.657
Function Knee Score 1.000
Gait assessment
Speed 0.112
Step length 1.00
Cadence 0.030
K1 0.885
K2 0.471
K3 0.471
Wext 0.112
C 0.471
Index of co-contraction 0.112
Time phase EpEk 0.030
Signiﬁcant differences are typed in bold.parameters of gait has not yet been established4,5. The
results of this study show mainly that celecoxib treatment
improved the efﬁciency of the locomotor mechanism.
During walking, CMb displacement can be compared to
the displacement of an inverted pendulum. At each stride,
the CMb is successively behind, or in front of the point of
contact with the foot on the ground. When the CMb is behind
the point of contact, the link to the ground causes a forward
deceleration (therefore a decrease in kinetic energy) and
a vertical rise in the CMb (therefore an increase in
gravitational potential energy). Some of the kinetic energy
due to the forward speed is converted into gravitational
potential energy. As the CMb moves past the point of contact
on the ground, the link to the ground allows a decrease in
the height of the CMb and a concomitant increase in the
Fig. 1. (A) Mean VAS score expressed in millimetre at each
assessment. Grey rectangles represent the placebo values; white
rectangles represent the celecoxib values. Vertical bars indicate the
standard deviations. Asterisk indicates the signiﬁcant results. (B)
Mean cadence expressed in step min1 at each assessment. f0
indicates optimal step frequency calculated according to a purely
ballistic movement (see Method). (C) Mean locomotor mechanism
(R expressed in %) at each assessment.
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is converted back into kinetic energy like a pendulum.
However, humans are not ideal frictionless pendulums, so
the kinetic and potential energy is not perfectly conserved.
The recovery is a measure of the amount of muscular work
undertaken during the pendulum exchange between poten-
tial and kinetic energy, and attains a maximum of 65%
during normal gait at optimal speed14. The recovery is
a good reﬂection of the efﬁcacy of the locomotor mecha-
nism in a pathological gait15. In this study, we have shown
that recovery was signiﬁcantly improved by celecoxib
treatment with a concomitant decrease in pain as indicated
by a signiﬁcant decrease of VAS knee pain score. As knee
pain decreased, the stride cadence increased with an
increase in leg stiffness. The increase in stride cadence
increases whole-body vertical stiffness16 and is accompa-
nied by a tendency to shift from a compliant towards a rigid
mechanism of walking. The marked increase in cadence
suggests that the contractile component of muscles pro-
gressively plays a less important role, when compared with
their elastic component. An increase in cadence requires a
stiffer spring (more contracting ﬁbres in the leg muscles)17.
The more the cadence increases, the more rigid are the
body structures connecting the body mass centre and the
line connecting the centre of mass with the ground. This
stiffer spring generates a shift towards a rigid mechanism of
walking revealed by an increase in the percentage of re-
covery. The increase in cadence enables one to get nearer
the optimal step frequency ( f0) calculated according to
a purely ballistic movement, without muscular contraction.
Thus the increase in cadence improves the efﬁciency of the
locomotor mechanism following treatment with celecoxib.
Conclusion
This study has shown that celecoxib improves the
efﬁciency of the locomotor mechanism and conﬁrmed
previous studies1,4 that have demonstrated clinical efﬁcacy
for reduction of knee pain in patients with OA.
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Annexe: glossary abbreviation
BF: Biceps Femoris muscle.
C: net oxygen cost.
CMb: the centre of the body of mass.
Ekf: kinetic energy of the CMb due to its velocity in the
forward direction.
Ekl: kinetic energy of the CMb due to its velocity in the
lateral direction.
Ekv: kinetic energy of the CMb due to its velocity in the
vertical direction.
Ep: gravitational potential energy of the CMb.
GRF: ground reaction forces.
Hz: Hertz.
K1: knee ﬂexion at heel strike.
K2: maximum knee ﬂexion at loading response.
K3: maximum knee ﬂexion at swing phase.
Recovery: percentage of energy recovered over a stride by
an interchange between potential and kinetic
energy.
RF: Rectus Femoris muscle.
RQ: respiratory quotient: ratio between the rate of carbon
dioxide production and the rate of oxygen consump-
tion.
Sv: vertical CMb displacement.
Wekf: work to accelerate the CMb in forward direction.
Wekl: work to accelerate the CMb in lateral direction.
Wekv: work to accelerate the CMb in vertical direction.
Wep: positive work to lift the CMb.
Wext: positive mechanical work performed by muscles to lift
and accelerate the CMb.
